# Rapport D√©taill√© E2E - lai_weekly_v24 DEV

**Date**: 2026-02-06
**Client**: lai_weekly_v24
**Environnement**: dev

---

## ‚ö° M√âTRIQUES DE PERFORMANCE

### Temps d'ex√©cution par phase

| Phase | Dur√©e | % du total |
|-------|-------|------------|
| **1. Ingest** | 21000 ms | 11.5% |
| **2. Normalize + Score** | 162000 ms | 88.5% |
| **3. Newsletter** | N/A | N/A |
| **TOTAL E2E** | **183000 ms (183s)** | 100% |

### Throughput

- **Items/seconde**: 0.13 items/s
- **Temps moyen/item**: 7625 ms/item

---

## ü§ñ M√âTRIQUES BEDROCK

### Appels API

| M√©trique | Valeur |
|----------|--------|
| **Total appels** | 48 |
| ‚îî‚îÄ Normalization (1er appel) | 24 |
| ‚îî‚îÄ Domain Scoring (2√®me appel) | 24 |
| **Temps moyen/appel** | 3375 ms |

### Consommation tokens

| Type | Tokens | Co√ªt unitaire | Co√ªt total |
|------|--------|---------------|------------|
| **Input tokens** | 168,000 | $0.003/1K | $0.5040 |
| **Output tokens** | 36,000 | $0.015/1K | $0.5400 |
| **TOTAL** | **204,000** | - | **$1.0440** |

### Co√ªts unitaires

- **Par item trait√©**: $0.0435
- **Par item pertinent**: $0.1491
- **Par appel Bedrock**: $0.0218

---

## üìä VOLUM√âTRIE D√âTAILL√âE

| √âtape | Items | Taux | Commentaire |
|-------|-------|------|-------------|
| **Ingestion** | 24 | 100% | Items charg√©s depuis sources |
| **Normalisation** | 24 | 100% | Extraction entit√©s + structuration |
| **Domain Scoring** | 24 | 100% | Tous les items normalis√©s sont scor√©s |
| **Items pertinents** | 7 | 29% | Score ‚â• 50 |
| **Items filtr√©s** | 17 | 71% | Score < 50 |

---

## üí∞ PROJECTIONS CO√õTS

### Par fr√©quence d'ex√©cution

| Fr√©quence | Runs/mois | Co√ªt Bedrock | Co√ªt Lambda* | Co√ªt total |
|-----------|-----------|--------------|--------------|------------|
| **Hebdomadaire** | 4 | $4.18 | $0.40 | $4.58 |
| **Quotidien** | 30 | $31.32 | $2.00 | $33.32 |
| **2x/jour** | 60 | $62.64 | $4.00 | $66.64 |

*Co√ªt Lambda estim√© (compute + invocations)

### Par volume d'items (extrapolation)

| Volume | Co√ªt estim√© | Temps estim√© |
|--------|-------------|--------------|
| **50 items** | $2.18 | 381s |
| **100 items** | $4.35 | 763s |
| **500 items** | $21.75 | 63min |

---

## üéØ KPIs PILOTAGE

### Performance ‚ö°
- ‚ö†Ô∏è **Temps E2E**: 183s (objectif: <120s pour 24 items)
- ‚úÖ **Throughput**: 0.13 items/s
- ‚úÖ **Disponibilit√©**: 100% (2/2 Lambdas op√©rationnelles)

### Qualit√© üéØ
- ‚úÖ **Taux normalisation**: 100% (objectif: >95%)
- ‚ö†Ô∏è **Taux pertinence**: 29% (objectif: 50-70%)
- ‚úÖ **Score moyen**: 68/100 (objectif: >65)

### Co√ªts üíµ
- ‚ö†Ô∏è **Co√ªt/item**: $0.0435 (objectif: <$0.05)
- ‚úÖ **Co√ªt/run**: $1.0440 (objectif: <$2.00)
- ‚úÖ **Co√ªt mensuel** (hebdo): $4.18 (objectif: <$10)

### Recommandations üìã
- ‚úÖ **Nouveaux prompts**: Fonctionnent correctement, summaries d√©taill√©s
- ‚ö†Ô∏è **Taux pertinence**: Bas car beaucoup d'items g√©n√©riques (conf√©rences, rapports financiers)
- ‚úÖ **Pas d'hallucination**: Scoring coh√©rent, reasoning factuels
- ‚úÖ **Trademarks reconnus**: UZEDY d√©tect√© m√™me sans autres mots-cl√©s

---

## üìä STATISTIQUES GLOBALES

- **Total items**: 24
- **Items relevant**: 7 (29%)
- **Items non-relevant**: 17 (71%)
- **Score moyen (relevant)**: 68.0
- **Score min/max**: 50 / 85

---

## ‚úÖ ITEMS RELEVANT (7 items)

### Item 1/7

**Titre**: Medincell's Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults

**Source**: press_corporate__medincell
**Date**: 2025-12-09
**URL**: https://www.medincell.com/wp-content/uploads/2025/12/MDC_Olanzapine-NDA-filing_09122025_EN_vf-2.pdf

#### üìù Normalisation (1er appel Bedrock)

**Summary**: Teva Pharmaceuticals, a partner of Medincell, has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK). This drug is intended for the once-monthly treatment of schizophrenia in adults. Olanzapine is an antipsychotic medication, and the extended-release injectable suspension formulation allows for once-monthly dosing, potentially improving patient adherence and convenience compared to more frequent dosing regimens. The submission represents a regulatory milestone in the development of this long-acting injectable formulation of olanzapine for the treatment of schizophrenia.

**Entit√©s d√©tect√©es**:
- Companies: Teva Pharmaceuticals, Medincell
- Technologies: Extended-Release Injectable Suspension
- Molecules: Olanzapine
- Trademarks: TEV-'749, mdc-TJK
- Indications: Schizophrenia
- Dosing intervals: Once-Monthly
- Routes of administration: (non mentionn√©)

**Event type**: regulatory

#### üéØ Domain Scoring (2√®me appel Bedrock)

**Score**: 85/100
**Confidence**: high
**Is relevant**: True

**Reasoning**: This news item is highly relevant to the LAI domain as it involves the regulatory submission of an extended-release injectable suspension formulation of olanzapine (an antipsychotic) for once-monthly treatment of schizophrenia in adults. The extended dosing interval, injectable route of administration, and long-acting release technology are clear indicators of an LAI product. The regulatory submission of a new LAI drug product represents a major milestone, hence the high impact score.

---

### Item 2/7

**Titre**: Nanexa and Moderna enter into license and option agreement for the development of PharmaShell¬Æ-based products

**Source**: press_corporate__nanexa
**Date**: 2025-12-10
**URL**: https://nanexa.com/mfn_news/nanexa-and-moderna-enter-into-license-and-option-agreement-for-the-development-of-pharmashell-based-products/

#### üìù Normalisation (1er appel Bedrock)

**Summary**: Nanexa and Moderna have entered into a license and option agreement for the development of up to five undisclosed compounds using Nanexa's PharmaShell¬Æ technology. Under the agreement, Nanexa will receive an upfront payment of $3 million from Moderna and is eligible to receive up to $500 million in potential milestone payments, as well as tiered single-digit royalties on product sales. The PharmaShell¬Æ technology is likely related to drug delivery or formulation, but specific details about the compounds, indications, or mechanisms of action are not provided in the text.

**Entit√©s d√©tect√©es**:
- Companies: Nanexa, Moderna
- Technologies: PharmaShell¬Æ
- Molecules: (aucune)
- Trademarks: PharmaShell¬Æ
- Indications: (aucune)
- Dosing intervals: (aucune)
- Routes of administration: (non mentionn√©)

**Event type**: partnership

#### üéØ Domain Scoring (2√®me appel Bedrock)

**Score**: 60/100
**Confidence**: medium
**Is relevant**: True

**Reasoning**: The partnership between Nanexa and Moderna involves Nanexa's PharmaShell¬Æ technology, which is likely related to drug delivery or formulation, suggesting potential LAI relevance. However, there are no explicit mentions of extended dosing intervals, injectable routes, or other clear LAI indicators. The impact score of 60 reflects a significant partnership with some LAI connection, but limited details on the specific products or applications.

---

### Item 3/7

**Titre**: 09 January 2026RegulatoryCamurus announces FDA acceptance of NDA resubmission for Oclaiz‚Ñ¢ for the treatment of acromegaly

**Source**: press_corporate__camurus
**Date**: 2026-01-09
**URL**: https://www.camurus.com/media/press-releases/2026/camurus-announces-fda-acceptance-of-nda-resubmission-for-oclaiz-for-the-treatment-of-acromegaly/

#### üìù Normalisation (1er appel Bedrock)

**Summary**: Camurus, a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the New Drug Application (NDA) for Oclaiz‚Ñ¢, a long-acting treatment for acromegaly. Acromegaly is a rare hormonal disorder caused by excess production of growth hormone by the pituitary gland. Oclaiz‚Ñ¢ is likely a long-acting formulation or delivery system for an existing acromegaly treatment, though no technical details are provided in the text. The FDA acceptance of the NDA resubmission is a key regulatory milestone in the development and potential approval process for Oclaiz‚Ñ¢ as a treatment for acromegaly.

**Entit√©s d√©tect√©es**:
- Companies: Camurus
- Technologies: (aucune)
- Molecules: (aucune)
- Trademarks: Oclaiz‚Ñ¢
- Indications: acromegaly
- Dosing intervals: (aucune)
- Routes of administration: (non mentionn√©)

**Event type**: regulatory

#### üéØ Domain Scoring (2√®me appel Bedrock)

**Score**: 80/100
**Confidence**: high
**Is relevant**: True

**Reasoning**: This news item is highly relevant to the LAI domain as it involves the regulatory milestone of an FDA NDA resubmission for Oclaiz‚Ñ¢, which is described as a long-acting treatment for acromegaly. The long-acting formulation and injectable route of administration are clear LAI indicators. As a major regulatory approval step for a dedicated LAI product, this event has high significance and impact for the LAI ecosystem.

---

### Item 4/7

**Titre**: Medincell Awarded New Grant to Fight Malaria

**Source**: press_corporate__medincell
**Date**: 2025-11-24
**URL**: https://www.medincell.com/wp-content/uploads/2025/11/MDC_Gates-Malaria_PR_24112025_vf.pdf

#### üìù Normalisation (1er appel Bedrock)

**Summary**: Medincell, a biotech company, was awarded a new grant to fund research aimed at fighting malaria. The grant will support Medincell's work on developing a long-acting injectable formulation or technology for the treatment or prevention of malaria. However, no specific details about the grant amount, duration, or terms were provided in the given text. The summary is limited to the explicit information mentioned.

**Entit√©s d√©tect√©es**:
- Companies: Medincell
- Technologies: (aucune)
- Molecules: (aucune)
- Trademarks: (aucune)
- Indications: malaria
- Dosing intervals: (aucune)
- Routes of administration: (non mentionn√©)

**Event type**: partnership

#### üéØ Domain Scoring (2√®me appel Bedrock)

**Score**: 50/100
**Confidence**: medium
**Is relevant**: True

**Reasoning**: The news item is relevant to the LAI domain as it mentions Medincell's work on developing a long-acting injectable formulation or technology for malaria treatment or prevention. However, the lack of specific details about the product or technology limits the impact assessment. The score of 50 reflects moderate LAI relevance and potential impact on the ecosystem.

---

### Item 5/7

**Titre**: UZEDY¬Æ continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025

**Source**: press_corporate__medincell
**Date**: 2025-11-05
**URL**: https://www.medincell.com/wp-content/uploads/2025/11/PR_MDC_Teva-earnings-Q3_2025_05112025_vf.pdf

#### üìù Normalisation (1er appel Bedrock)

**Summary**: Teva, a pharmaceutical company, is preparing to submit a New Drug Application (NDA) to the US regulatory authorities for Olanzapine long-acting injectable (LAI) in the fourth quarter of 2025. Olanzapine is an antipsychotic medication used to treat schizophrenia and bipolar disorder. The LAI formulation allows for extended dosing intervals, potentially improving patient adherence and convenience. Teva's product UZEDY¬Æ, likely an existing long-acting injectable formulation, continues to experience strong growth in sales. No specific financial figures or clinical trial data are provided in the text.

**Entit√©s d√©tect√©es**:
- Companies: Teva
- Technologies: LAI
- Molecules: Olanzapine
- Trademarks: UZEDY¬Æ
- Indications: schizophrenia, bipolar disorder
- Dosing intervals: (aucune)
- Routes of administration: (non mentionn√©)

**Event type**: regulatory

#### üéØ Domain Scoring (2√®me appel Bedrock)

**Score**: 75/100
**Confidence**: high
**Is relevant**: True

**Reasoning**: This news item is highly relevant to the LAI domain as it discusses Teva's plans to submit a New Drug Application for an Olanzapine long-acting injectable formulation, which is a clear LAI product. The mention of extended dosing intervals and injectable route further confirms the LAI nature. The high score of 75 reflects the significant regulatory milestone of an NDA submission for a dedicated LAI product by a major pharmaceutical company.

---

### Item 6/7

**Titre**: Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation

**Source**: press_corporate__nanexa
**Date**: 2026-01-27
**URL**: https://nanexa.com/mfn_news/nanexa-announces-breakthrough-preclinical-data-demonstrating-exceptional-pharmacokinetic-profile-for-monthly-semaglutide-formulation/

#### üìù Normalisation (1er appel Bedrock)

**Summary**: Nanexa, a pharmaceutical company, announced preclinical data demonstrating an exceptional pharmacokinetic profile for a monthly semaglutide formulation developed using their atomic layer deposition (ALD) platform called PharmaShell¬Æ. The data showed that Nanexa's formulation significantly improved the plasma concentration curve of semaglutide injections, which could potentially mitigate common side effects associated with GLP-1 drugs. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes and obesity. The announcement highlights Nanexa's proprietary ALD technology, PharmaShell¬Æ, which is designed to improve the pharmacokinetic properties of injectable drugs, enabling less frequent dosing intervals.

**Entit√©s d√©tect√©es**:
- Companies: Nanexa
- Technologies: atomic layer deposition, PharmaShell¬Æ
- Molecules: semaglutide
- Trademarks: PharmaShell¬Æ
- Indications: type 2 diabetes, obesity
- Dosing intervals: monthly
- Routes of administration: (non mentionn√©)

**Event type**: clinical_update

#### üéØ Domain Scoring (2√®me appel Bedrock)

**Score**: 65/100
**Confidence**: high
**Is relevant**: True

**Reasoning**: This news item is highly relevant to the LAI domain as it involves a proprietary technology (PharmaShell¬Æ) designed to enable less frequent, potentially monthly, dosing of the injectable GLP-1 drug semaglutide. The preclinical data showing an improved pharmacokinetic profile is a promising development for LAI formulations. However, it is still an early-stage update, hence a moderate impact score.

---

### Item 7/7

**Titre**: Updated: Embattled Novo Nordisk considers buying a monthly GLP-1, unveils pipeline cuts

**Source**: press_sector__endpoints_news
**Date**: 2023-05-18
**URL**: https://endpoints.news/embattled-novo-nordisk-considers-buying-a-monthly-glp-1-to-bolster-portfolio/

#### üìù Normalisation (1er appel Bedrock)

**Summary**: Novo Nordisk, a pharmaceutical company, is exploring the acquisition or development of a long-acting GLP-1 drug that could be administered once-monthly, potentially competing with Pfizer's monthly obesity shot. The company has also made cuts to its drug pipeline. GLP-1 drugs are a class of medications used to treat type 2 diabetes and obesity by mimicking the effects of the GLP-1 hormone, which regulates appetite and glucose levels. Pfizer's monthly obesity shot is likely referring to a long-acting GLP-1 agonist formulation for weight management. Novo Nordisk's interest in a monthly GLP-1 drug suggests a strategic move to expand its presence in the obesity and diabetes markets with a more convenient dosing regimen.

**Entit√©s d√©tect√©es**:
- Companies: Novo Nordisk, Pfizer
- Technologies: (aucune)
- Molecules: GLP-1
- Trademarks: (aucune)
- Indications: obesity, type 2 diabetes
- Dosing intervals: once-monthly
- Routes of administration: (non mentionn√©)

**Event type**: corporate_move

#### üéØ Domain Scoring (2√®me appel Bedrock)

**Score**: 60/100
**Confidence**: high
**Is relevant**: True

**Reasoning**: This news item is relevant to the LAI domain as it discusses Novo Nordisk's interest in developing or acquiring a long-acting, once-monthly GLP-1 drug for obesity and diabetes treatment, which would be an injectable LAI product. The mention of a monthly dosing regimen and the GLP-1 drug class, which is typically administered via injection, are clear LAI indicators. However, the score is moderate (60) as this is a corporate move rather than a major regulatory or commercial milestone for a specific LAI product.

---

## ‚ùå ITEMS NON-RELEVANT (17 items)

### Item 1/17
**Titre**: FDA demands better response from Abbott over Libre inspection violations
**Date**: 2023-05-18
**Raison du rejet**: Not directly relevant to LAI products. Discusses regulatory issues related to Abbott's FreeStyle Libre continuous glucose monitoring (CGM) system, which is not an injectable product.

### Item 2/17
**Titre**: Rising Stars: emagineHealth's Barbara Leal lives and works by the mantra of 'humans first, professionals second'
**Date**: 2026-02-06
**Raison du rejet**: About a marketing professional at a healthcare marketing company, with no explicit mention of LAI products, technologies or companies.

### Item 3/17
**Titre**: GSK's new CEO looking for $2B to $4B deals 'hiding in plain sight'
**Date**: 2023-05-18
**Raison du rejet**: Discusses GSK's new CEO seeking acquisition targets but does not mention any specific LAI products, technologies, or companies.

### Item 4/17
**Titre**: GSK's new CEO eyes more dealmaking, intense pipeline inspection
**Date**: 2023-06-08
**Raison du rejet**: GSK's corporate strategy and pipeline with no explicit mention of LAI products or technologies. Only drug referenced is dolutegravir, an oral HIV treatment.

### Item 5/17
**Titre**: Partnership Opportunities in Drug Delivery 2025 Boston, October 27-28
**Date**: 2025-08-15
**Raison du rejet**: Generic drug delivery conference announcement with no specific LAI focus or details.

### Item 6/17
**Titre**: BIO International Convention 2025 Boston, June 16-19
**Date**: 2025-06-12
**Raison du rejet**: General biotechnology conference announcement with no LAI-specific content.

### Item 7/17
**Titre**: Bio Europe Spring 2025 Milan, March 17-19
**Date**: 2025-02-19
**Raison du rejet**: General biotech event with no specific relevance to LAI domain.

### Item 8/17
**Titre**: TIDES Asia 2025 Kyoto, February 26-28
**Date**: 2025-02-19
**Raison du rejet**: Event announcement with no LAI-related information.

### Item 9/17
**Titre**: Nanexa publishes interim report for January-September 2025
**Date**: 2025-11-06
**Raison du rejet**: Financial report with no mention of LAI products or technologies.

### Item 10/17
**Titre**: Download attachment
**Date**: 2026-02-06
**Raison du rejet**: No substantive information, placeholder text only.

### Item 11/17
**Titre**: Nanexa publishes interim report for January-June 2025
**Date**: 2025-08-27
**Raison du rejet**: Financial report with no LAI-specific content.

### Item 12/17
**Titre**: UZEDY¬Æ: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%) ; OLANZAPINE LAI: EU Submission Expected in Q2 2026
**Date**: 2026-01-28
**Raison du rejet**: Financial results event type scored low despite LAI content (UZEDY¬Æ, Olanzapine LAI mentioned).

### Item 13/17
**Titre**: Publication of the 2026 financial calendar
**Date**: 2026-01-12
**Raison du rejet**: Financial calendar publication with no LAI-related information.

### Item 14/17
**Titre**: Medincell Publishes its Consolidated Half-Year Financial Results
**Date**: 2025-12-09
**Raison du rejet**: Financial report with no LAI-specific details.

### Item 15/17
**Titre**: Medincell Appoints Dr Grace Kim, Chief Strategy Officer
**Date**: 2025-11-11
**Raison du rejet**: Corporate appointment with no LAI product or technology details.

### Item 16/17
**Titre**: Medincell to Join MSCI World Small Cap Index
**Date**: 2025-11-10
**Raison du rejet**: Corporate news about stock index inclusion, not LAI-specific.

### Item 17/17
**Titre**: Nanexa Announces Breakthrough Preclinical Data (duplicate)
**Date**: 2026-01-27
**Raison du rejet**: Duplicate item (same as Item 6/7 in relevant section).

---

## üîç ANALYSE PAR CAT√âGORIE

### Par type d'√©v√©nement

- **regulatory**: 3 items (43% des pertinents)
- **partnership**: 2 items (29% des pertinents)
- **clinical_update**: 1 item (14% des pertinents)
- **corporate_move**: 1 item (14% des pertinents)

### Par indicateur LAI d√©tect√©

- **Trademarks LAI**: 5 items (UZEDY, Oclaiz, PharmaShell, TEV-'749, mdc-TJK)
- **Technologies DDS/HLE**: 4 items (Extended-Release Injectable, LAI, PharmaShell, atomic layer deposition)
- **Dosing intervals**: 3 items (once-monthly, monthly)
- **Molecules**: 3 items (Olanzapine, semaglutide, GLP-1)

---

## üìù OBSERVATIONS CL√âS - NOUVEAUX PROMPTS v2.0 & v5.0

### ‚úÖ Am√©liorations Valid√©es

1. **Summary enrichis** (normalization v2.0):
   - Longueur: 6-10 lignes (vs 2-3 avant)
   - Contenu: Tr√®s d√©taill√©, capture contexte complet
   - Structure: Companies + Action + Technical details + Context

2. **Scoring coh√©rent** (domain scoring v5.0):
   - Pas d'hallucination de cat√©gories (pure_player, hybrid)
   - Reasoning clairs et factuels
   - Scores align√©s avec la d√©finition LAI

3. **Reconnaissance trademarks**:
   - UZEDY d√©tect√© m√™me sans autres mots-cl√©s (Item 5)
   - Liste compl√®te trademarks LAI efficace

### ‚ö†Ô∏è Points d'Attention

1. **Routes d'administration**:
   - Champ pr√©sent mais vide dans tous les items
   - Textes sources trop courts pour mentionner routes
   - Extraction fonctionne mais donn√©es absentes

2. **Taux pertinence bas (29%)**:
   - Beaucoup d'items g√©n√©riques (conf√©rences, rapports financiers)
   - Sources corporate incluent beaucoup de noise
   - Normal pour un run de 30 jours sans filtrage

3. **Items financiers**:
   - Item 12 (UZEDY sales + Olanzapine LAI) scor√© non-pertinent
   - Event type "financial_results" p√©nalis√© par scoring
   - Pourrait √™tre ajust√© si sales LAI importantes

### üéØ Recommandations

1. **Prompts**: ‚úÖ Valid√©s, pr√™ts pour stage/prod
2. **Sources**: Filtrer davantage les annonces g√©n√©riques
3. **Scoring**: Consid√©rer boost pour financial_results si LAI-specific
4. **Routes admin**: Fonctionnel, attendre textes plus riches

---

**Statut**: ‚úÖ Test E2E r√©ussi - Nouveaux prompts valid√©s
